phenylethanolamine a

Phenylethanolamine A is a β-adrenergic agonist and a byproduct of the Ractopamine synthesis process.

2-Octanone inhibits fatty acid synthase in rats and exhibits weak inhibitory activity against phenylethanolamine N-methyltransferase, and is widely used in biochemical experiments and drug synthesis research.

Sunagrel, a derivative of phenylethanolamine, was patented by Maggioni Farmaceutici S.p.A., primarily serving as an inhibitor of platelet aggregation and an antilipidaemic agent.

LY 78335 (1-(2,3-Dichlorophenyl)ethanamine hydrochloride) is a phenylethanolamine-N-methyltransferase (PNMT) inhibitor.

LY 87130 is a phenylethanolamine-N-methyltransferase inhibitor.

LY-79771 is a phenylethanolamine anti-obesity agent, which can effectively prevent fat recovery after energy deprivation.

PNMT-IN-1 (inhibitor 4) is a selective second generation inhibitor [1] of phenylethanolamine N-methyltransferase (PNMT), exhibiting a Ki value of 1.2 nM and an IC50 value of 81 nM. Additionally, it disrupts the activity of DNMT1 and DNMT3b, with IC50 values of 61 μM and 17 μM, respectively, and antagonizes the action of epinephrine.

Phenylethanolamine N-methyl transferase, bovine, is a biocatalyst and a pivotal enzyme in emerging biocatalyst technology. Enzyme engineering focuses on improving reaction kinetics, substrate selectivity, and activity in extreme conditions (e.g., low or high pH). Modifying these enzymes to introduce stimulus responsiveness also enables dynamic control of their activity.